THE 2-MINUTE RULE FOR MBL77

For people with symptomatic disease requiring therapy, ibrutinib is commonly encouraged depending on 4 phase III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and various generally utilised CIT combinations, particularly FCR, bendamustine moreover rituximab and chlorambucil moreover obinutuzumab (ClbO).107–109 I